Австралия - английски - Department of Health (Therapeutic Goods Administration)

henry schein halas -

Канада - английски - Health Canada

sandoz canada incorporated - zoledronic acid (zoledronic acid monohydrate) - solution - 5mg - zoledronic acid (zoledronic acid monohydrate) 5mg - bone resorption inhibitors

САЩ - английски - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - norethindrone 0.35 mg - progestin-only oral contraceptives are indicated for the prevention of pregnancy. if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. however, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. table 1 lists the pregnancy rates for users of all major methods of contraception.   % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year method (1) typical use (2) perfect use (3) (4) no method4 85 85 spermicides 28 18 42 fertility awareness-based methods 24 47 standard days method6 5 twoday method6 4 ovulation method6 3 symptothermal method6 0.4 withdrawal 22 4 46 sponge 36 parous women 24 20 nulliparous women 12 9 condom7 female (fc) 21 5 41 male 18 2 43 diaphragm8 12 6 57 combined pill and progestin-only pill 9 0.3 67 norelgestromin and ethinyl estradiol patch 9 0.3 67 nuvaring 9 0.3 67 depo-provera 6 0.2 56 intrauterine contraceptives paragard (copper t) 0.8 0.6 78 mirena (lng) 0.2 0.2 80 implanon 0.05 0.05 84 female sterilization 0.5 0.5 100 male sterilization 0.15 0.10 100 notes: norethindrone tablets have not been studied for and are not indicated for use in emergency contraception. progestin-only oral contraceptives (pops) should not be used by women who currently have the following conditions:

САЩ - английски - NLM (National Library of Medicine)

physicians total care, inc. - norgestrel (unii: 3j8q1747z2) (norgestrel - unii:3j8q1747z2), ethinyl estradiol (unii: 423d2t571u) (estradiol - unii:4ti98z838e) - norgestrel 0.3 mg - low-ogestrel® (norgestrel and ethinyl estradiol tablets usp, 0.3 mg/0.03 mg) is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception.1 the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. oral contraceptives should not be used in women who have the following conditions: - thrombophlebitis or thromboembolic disorders thrombophlebitis or thromboembolic disorders - a past history of deep vein thrombophlebitis or thromboembolic disorders a past history of deep vein thrombophlebitis or thromboembolic disorders - cerebral vascular or coronary artery disease cerebral vascular or coronary artery disease - known or suspected carcinoma of the

САЩ - английски - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization and the iud, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. table i: percentage of women experiencing an unintended pregnancy during the first year of use of a contraceptive method method perfect use typical use levonorgestrel implants 0.05 0.05 male sterilization 0.1 0.15 female sterilization 0.5 0.5 depo-provera® (injectable progestogen) 0.3 0.3 oral contraceptives 5 combined 0.1 na progestin only 0.5 na iud progesterone 1.5 2 copper t 380a 0.6 0.8 condom (male) without spermicide 3 14 (female) without spermicide 5 21 cervical cap nulliparous women 9 20 par

САЩ - английски - NLM (National Library of Medicine)

physicians total care, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.050 mg - oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization and the iud, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. oral contraceptives should not be used in women with any of the following conditions: - thrombophlebitis or thromboembolic disorders. - a past history of deep-vein thrombophlebitis or thromboembolic disorders. - cerebral-vascular or coronary-artery disease. - known or suspected carcinoma of the breast. - carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia. - undiagnosed abnormal genital bleeding. - cholestatic jaundice of pregnancy or jaundice with prior pill use. - h

САЩ - английски - NLM (National Library of Medicine)

rebel distributors corp - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.050 mg - oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization and the iud, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. oral contraceptives should not be used in women with any of the following conditions: - thrombophlebitis or thromboembolic disorders. - a past history of deep-vein thrombophlebitis or thromboembolic disorders. - cerebral-vascular or coronary-artery disease. - known or suspected carcinoma of the breast. - carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia. - undiagnosed abnormal genital bleeding. - cholestatic jaundice of pregnancy or jaundice with prior pill use. - h

САЩ - английски - NLM (National Library of Medicine)

physicians total care, inc. - norgestrel (unii: 3j8q1747z2) (norgestrel - unii:3j8q1747z2), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norgestrel 0.3 mg - oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization and the iud, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. oral contraceptives should not be used in women with any of the following conditions: thrombophlebitis or thromboembolic disorders. a past history of deep-vein thrombophlebitis or thromboembolic disorders. cerebral-vascular or coronary-artery disease. known or suspected carcinoma of the breast. carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia. undiagnosed abnormal genital bleeding. cholestatic jaundice of pregnancy or jaundice with prior pill use. hepatic adenomas

САЩ - английски - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - norethindrone 0.35 mg - progestin-only oral contraceptives are indicated for the prevention of pregnancy. if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. however, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. table 1 lists the pregnancy rates for users of all major methods of contraception. ortho micronor® tablets have not been studied for and are not indicated for use in emergency contraception. progestin-only oral contraceptives (pops) should not be used by women who currently have the following conditions: - known or suspected pregnancy - known or suspected carcinoma of the breast - undiagnosed abnormal genital bleeding - hypersensitivity to any component of this product - benign or malignant liver tumors - acute liver disease - it's best to take your first pop on the first day of your menstrual period (day 1 start). if you use a day 1 start, you are protected from becoming pregnant as soon as you take your first pill. - if you decide to tak

САЩ - английски - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - norethindrone 0.35 mg - 1. indications progestin-only oral contraceptives are indicated for the prevention of pregnancy. 2. efficacy if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. however, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. table 1 lists the pregnancy rates for users of all major methods of contraception. method (1) % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year * typical use † (2) perfect use ‡ (3) (4) no method§ 85 85 spermicides¶ 28 18 42 fertility awareness-based methods 24 47    standard days method# 5       two day method# 4    ovulation method# 3    symptothermal# 0.4 withdrawal 22 4 46 sponge 36    parous women 24 20    nulliparous women 12 9 condomÞ    female (fc) 21 5 41    male 18 2 43 diaphragmß 12 6 57 combined pill and progestin-only pill 9 0.3 67 norelgestromin and ethinyl estradiol patch 9 0.3 67 nuvaring 9 0.3 67 depo-provera 6 0.2 56 intrauterine co